Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Bought by Invesco Ltd.

Invesco Ltd. raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,060,263 shares of the company’s stock after buying an additional 24,392 shares during the period. Invesco Ltd. owned approximately 2.15% of Prestige Consumer Healthcare worth $82,796,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. HighTower Advisors LLC grew its holdings in Prestige Consumer Healthcare by 4.9% during the 3rd quarter. HighTower Advisors LLC now owns 16,708 shares of the company’s stock worth $1,215,000 after acquiring an additional 774 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Prestige Consumer Healthcare by 13.7% during the third quarter. Stifel Financial Corp now owns 19,299 shares of the company’s stock worth $1,391,000 after purchasing an additional 2,322 shares in the last quarter. Wellington Management Group LLP purchased a new position in Prestige Consumer Healthcare in the third quarter valued at $6,342,000. Jane Street Group LLC increased its holdings in Prestige Consumer Healthcare by 28.3% in the third quarter. Jane Street Group LLC now owns 65,373 shares of the company’s stock valued at $4,713,000 after buying an additional 14,434 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Prestige Consumer Healthcare in the third quarter valued at $264,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

PBH has been the subject of several analyst reports. DA Davidson increased their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Canaccord Genuity Group upped their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Oppenheimer boosted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Finally, StockNews.com lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Tuesday, April 8th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $82.17 on Monday. The company’s 50 day simple moving average is $84.56 and its 200-day simple moving average is $79.89. The firm has a market cap of $4.07 billion, a PE ratio of 19.24, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.